Yulareb Dosage & Drug Information

Concise Prescribing Info

Contents

Abemaciclib

Information is sourced from publicly available references. The information is for educational purpose of healthcare professionals and we are not liable for any loss or damage.

Indications/Uses

In combination w/ endocrine therapy for adjuvant treatment of adult patients w/ hormone receptor (HR) +ve, human epidermal growth factor receptor 2 (HER2) -ve, node +ve early breast cancer at high risk of recurrence. In combination w/ aromatase inhibitor as initial endocrine-based therapy for adult patients w/ HR +ve, HER2 -ve advanced or metastatic breast cancer. In combination w/ fulvestrant for adult patients w/ HR +ve, HER2 -ve advanced or metastatic breast cancer w/ disease progression following endocrine therapy.

Dosage/Direction for Use

Use in combination w/ fulvestrant, tamoxifen or aromatase inhibitor Recommended dose: 150 mg twice daily. Early breast cancer Continue Yulareb for 2 yr or until disease recurrence or unacceptable toxicity. Advanced or metastatic breast cancer Continue treatment until disease progression or unacceptable toxicity.

Administration

May be taken with or without food: Swallow whole, do not chew/crush/split.

Contraindications

Hypersensitivity.

MIMS Class

Targeted Cancer Therapy

ATC Classification

L01EF03 - abemaciclib ; Belongs to the class of cyclin-dependent kinase (CDK) inhibitors. Used in the treatment of cancer.

Regulatory Classification

POM

Presentation/Packing

Form

Yulareb FC tab 100 mg

Packing/Price

1's

Form

Yulareb FC tab 150 mg

Packing/Price

1's

Form

Yulareb FC tab 50 mg

Packing/Price

1's

Yulareb

abemaciclib

Manufacturer:

Lilly del Caribe